The embolic protection devices market is expected to grow at a compound annual growth rate of 7.63% over the forecast period to reach a market size of US$1,278.309 million in 2026 from US$764.000 million in 2019. Embolic protection devices (EPDs) have the potential to lower clinical complications by preventing or reducing plaque particles from reaching the distal bed. An embolism is a particle of material called an embolus that lodges on the inside of a blood artery and causes a blockage. It can take the shape of a blood clot, a fat globule, an air bubble, or a foreign substance. The embolism can occur after surgery as a result of any injury to the walls, resulting in the development of clots in that location. The removal of these plaques and debris is critical because they can develop blockages, which can be fatal. When it is not monitored, it produces microinfarcts and left ventricular dysfunction. The use of EDP during percutaneous cardiac procedures has helped in reducing the number of complications due to debris being released into the bloodstream and causing blockages in smaller vessels. The devices are intended to collect and remove particles that may become dislodged during operations.
These devices are regarded to be a part of the most dependable, evidence-based method for minimising periprocedural myocardial infarction and other severe cardiovascular events. This process is always accompanied by imaging systems to determine that the gadget is positioned correctly. These gadgets are, without a doubt, a crucial component of the operation, according to experts. There is currently some evidence that using embolic protection devices during carotid and saphenous vein transplant procedures decreases peri-procedural complication rates considerably. Furthermore, studies from single-center clinical series in native coronary arteries and renal arteries reveal that using embolic protection may enhance the safety of these operations. However, large randomised studies are required to statistically establish the therapeutic use of these devices, owing to the significantly low complication rates of these procedures even without the use of embolic protection devices.
Rising incidences of cardiovascular, peripheral, and neurovascular surgery, as well as substantial expenditures in embolic device R&D, are the primary drivers driving market development. The rising prevalence of Transcatheter Aortic Valve Replacement (TAVR) procedures, as well as growing customer awareness of embolic devices, are both driving market expansion. Furthermore, The alarming spike in the number of deaths has caught the government's attention, and as a result, more awareness initiatives are being implemented. This aspect is also helping to drive market growth.
Increasing Prevalence of Cardiovascular Diseases and Growing Awareness Towards Them
According to the Brain Aneurysm Foundation (BAF), an estimated 6.5 million people in the United States have an unruptured brain aneurysm each year, or one in every 50 people. The yearly rate of rupture is between 8 and 10 per 100,000 individuals. Furthermore, both the World Heart Federation (WHF) and World Health Organisation (WHO) report that cardiovascular disease is the number one cause of death globally, accounting for nearly 17 million deaths per year. According to World Population Prospects 2019 (United Nations, 2019), by 2050, one in every six persons worldwide will be over the age of 65, up from one in every eleven in 2019.
EPDs play a critical role in minimising complications caused by clogs in blood arteries caused by debris in the circulation. They are an integral element of the most dependable, evidence-based technique for minimising periprocedural MI and other severe cardiovascular events. Consequently, increasing the application of embolic protection devices to collect and remove debris that may be extricated during surgeries is one of the factors that will propel the embolic protection devices market forward in the coming years.
Furthermore, government agencies, non-governmental organisations (NGOs), and educational institutions from all over the world are conducting awareness campaigns to raise knowledge of cardiovascular and neurovascular illnesses and their potential treatments.
However, the availability of alternative treatments, such as drugs and medicines, as well as the high cost of medical equipment, may hamper market expansion.
Keystone Heart Ltd., a Venus Medtech Company, disclosed that it would perform the first international commercial case using The TriGUARD 3TM Cerebral Embolic Protection Device in October 2020. The TriGUARD 3 Cerebral Embolic Protection (CEP) Device had received the European CE Mark. It is built and designed in such a manner that it minimizes the danger of cerebral injury by diverting embolic particles away from the brain. During Transcatheter Aortic Valve Implantation (TAVI) and other surgical transcatheter cardiac operations, this is carried out from cerebral circulation.
Cardiovascular Systems, Inc., a medical device company developing and commercialising innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced in March 2021 that the WIRION® Embolic Protection System had been used on the first patients in the United States. WIRION is a distal embolic protection filter that captures thrombus and debris from all sorts of peripheral vascular intervention operations, including atherectomy. Embolic protection devices are generally used in arteries above the knee that have lengthy lesions, a high plaque burden, and inadequate runoff.
Furthermore in April 2021, Contego Medical, LLC, a leading developer of advanced cardiovascular devices, announced that the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard IEP System) have acquired CE Mark. The Neuroguard integrated embolic protection (IEP) device is designed to increase luminal diameter in patients with clinically severe carotid artery stenosis by capturing and removing embolic particles simultaneously during angioplasty and stenting. The European Community CE mark of approval was granted to the Neuroguard IEP System following research involving 67 patients with a one-year follow-up that revealed an overall success rate of 100%, with a stroke and mortality rate of 0% at 30 days.
COVID-19 has a major influence on 2020 globally. With Covid-19 cases growing worldwide, there is growing concerned about a lack of vital life-saving equipment and other essential medical supplies to prevent the spread of this pandemic and give the best possible care to those who have been exposed to the virus. Furthermore, until a pharmacological treatment is found, ventilators serve as an important treatment option for COVID-19 patients who may require critical care. Furthermore, there is a pressing need to accelerate the production process for a wide range of test kits (antibody tests, self-administered, and others).